Newron Pharmaceuticals S.p.A. header image

Newron Pharmaceuticals S.p.A.

NWRN

Equity

ISIN IT0004147952 / Valor 2791431

SIX Swiss Exchange (2026-08-05)
CHF 12.26+3.72%

Newron Pharmaceuticals S.p.A.
UMushroom community rating:

star star star star star
4.50 4 votes No rating yet
NegativeNeutralPositive

About company

Newron Pharmaceuticals S.p.A., established in 1999 and headquartered in Bresso, Italy, with a subsidiary in Morristown, New Jersey, is a biopharmaceutical company specializing in the development of innovative therapies for central and peripheral nervous system disorders. The company aims to expand its product portfolio through both internal research and development and strategic licensing and acquisition of novel compounds targeting the central nervous system (CNS) at various stages of development. Newron's shares are publicly traded on the SIX Swiss Exchange under the ticker symbol NWRN, as well as on the primary market of the Düsseldorf Stock Exchange and XETRA under the trading symbol NP5.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

77.9%1Y
128%3Y
450%5Y

Performance

58.8%1Y
65.9%3Y
73.7%5Y

Volatility

Market cap

303 M

Market cap (USD)

Daily traded volume (Shares)

69,429

Daily traded volume (Shares)

1 day high/low

8.99 / 8.39

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.50

4 votes
Performance:
starstarstarstarstar
3.25
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.50
Nature:
starstarstarstarstar
3.75
Uwe K.
Switzerland, 30 Mar 2025
star star star star star
Könnte interessant sein.
Caterina F
Switzerland, 26 Mar 2025
star star star star star
Worth paying attention to
Markus Fässler
Switzerland, 05 Feb 2024
star star star star star
Evenamide, Newron’s innovative drug to treat schizophrenia, has proven safe and effective in use for TRS patients.

EQUITIES OF THE SAME SECTOR

Illumina Inc
Illumina Inc Illumina Inc Valor: 1111080
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.55%USD 199.87
MEDICLIN AG
MEDICLIN AG MEDICLIN AG Valor: 1158721
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.92%EUR 4.32
Ste Virbac SA
Ste Virbac SA Ste Virbac SA Valor: 524407
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.15%EUR 338.50
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
8.88%USD 88.07
Baxter International Inc
Baxter International Inc Baxter International Inc Valor: 911702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.60%USD 27.33
Novartis Inc
Novartis Inc Novartis Inc Valor: 1200526
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.11%CHF 124.66
EssilorLuxottica SA
EssilorLuxottica SA EssilorLuxottica SA Valor: 497537
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.56%EUR 171.45
Bausch Health Companies Inc
Bausch Health Companies Inc Bausch Health Companies Inc Valor: 42260834
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.71%USD 6.28
Cassava Sciences Inc
Cassava Sciences Inc Cassava Sciences Inc Valor: 46983284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.67%USD 0.96
Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Inc Ligand Pharmaceuticals Inc Valor: 12015449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.59%USD 302.57